STOCK TITAN
  1. Home
  2. News
  3. IMVT

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Immunovant, Inc. (Nasdaq: IMVT) CEO to present at 42nd Annual J.P. Morgan Healthcare Conference
Positive
  • None.
Negative
  • None.

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am ET.

The presentation will be webcast live and can be accessed at https://www.immunovant.com/investors/news-events. An archived webcast will be available for a limited time on Immunovant’s website.

About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com.

Contact:
Chau Cheng, PhD, MBA
Vice President, Investor Relations
Immunovant, Inc.
info@immunovant.com


The CEO of Immunovant, Inc. (Nasdaq: IMVT), Pete Salzmann, M.D., will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024.

The webcast of the presentation by Immunovant, Inc. (Nasdaq: IMVT) CEO can be accessed at https://www.immunovant.com/investors/news-events.

Yes, an archived webcast will be available for a limited time on Immunovant’s website.
Stock IMVT logo
Immunovant Inc

NASDAQ:IMVT

IMVT Rankings

#1352 Ranked by Market Cap
#39 Ranked by Stock Gains
N/A Ranked by Dividends

IMVT Latest News

Mar 12, 2024
Immunovant Awarded U.S. Patent for IMVT-1402
Feb 12, 2024
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
Dec 20, 2023
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Nov 28, 2023
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
Nov 13, 2023
Immunovant to Present at Upcoming Investor Conferences

IMVT Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Finance, Financial Conglomerates, Health Technology, Biotechnology

About IMVT

immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.